Louis Navellier’s #1 Stock for 2022

On October 20, the man who recommended Google before anyone else will reveal his #1 stock pick for 2022 — for FREE — ticker symbol and all — in a special presentation.

Wed, October 20 at 4:00PM ET

AbbVie’s August Options Are a Steal

Abbott Laboratories (NYSE:ABT) just split itself in two, spinning off a new company dubbed AbbVie (NYSE:ABBV).

The old Abbott kept the “easy” part of the healthcare industry (devices and nutritionals), while Abbvie represents the more difficult part of the business (drugs and treatments). Of course, with difficulty comes the potential for more success — the margins on proprietary drugs are much higher than for devices and nutritionals.

We’ll get to what to do with this in a minute, but what I think you should look at is a bit longer-term, so we should review some background first.

The key drug already on the market for AbbVie is Humira, a $2 billion-plus-per-year treatment for arthritis and psoriasis that is growing almost by double digits before you include currency translations. While AbbVie does have other drugs, the only one that matters in the short run is Humira — if sales growth keeps up, the stock moves up, and vice versa.

The odds are in favor of AbbVie having serious success with Humira in 2013 despite increased competition in the rheumatoid arthritis (RA) marketplace. Why? Management will be more focused — and I am assuming salespeople will be better compensated — in a more narrowly focused company with higher overall margins than the old Abbott. Salespeople make drugs like Humira a success more than the efficacy of the drug compared to competitors. (If this sounds cynical, try to find a doctor’s office that isn’t plastered with posters, memo pads, mouse pads and other swag provided by drug salespeople.)

Still, there will be uncertain trading in ABBV for a while; it might take a quarter or two to see accelerated growth in Humira and other AbbVie drug sales, making an option play on the new company something to think of in terms of months, maybe even a year.

The August calls for AbbVie are thinly traded but are, in my mind, a compelling value — either the $35 strike, just a few cents out of the money and trading under $1.50, or the $40, which is trading around 30 cents.

Any significant movement in ABBV, and you could have a double or more.

My OptionsIncome Strategy Is So Effective, 93% of Investors Who Use It Make Money. This Special Video will teach you how to instantly add CASH to your account every week, every month and every quarter and NEVER put your portfolio at risk. Create Your Own “Extra Pay Day” Every Week.

Article printed from InvestorPlace Media, https://investorplace.com/2013/01/abbvies-august-options-are-a-steal/.

©2021 InvestorPlace Media, LLC